Search Filters
Format Format
Subjects Subjects
Subjects Subjects
Sort by Item Count (A-Z)
Filter by Count
humans (50) 50
female (40) 40
oncology (38) 38
index medicus (35) 35
middle aged (34) 34
aged (30) 30
adult (26) 26
male (26) 26
chemotherapy (23) 23
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
cancer (18) 18
treatment outcome (18) 18
breast neoplasms - drug therapy (16) 16
breast cancer (14) 14
care and treatment (14) 14
survival (14) 14
aged, 80 and over (13) 13
medicine, general & internal (13) 13
antineoplastic combined chemotherapy protocols - adverse effects (12) 12
bevacizumab (11) 11
breast neoplasms - pathology (11) 11
cancer therapies (11) 11
clinical trials (11) 11
metastasis (11) 11
quality of life (11) 11
survival analysis (11) 11
patients (10) 10
therapy (10) 10
capecitabine (9) 9
colorectal cancer (9) 9
combination (9) 9
disease-free survival (9) 9
hematology (9) 9
prognosis (9) 9
analysis (8) 8
antineoplastic combined chemotherapy protocols - administration & dosage (8) 8
neoplasm metastasis (8) 8
paclitaxel (8) 8
research (8) 8
studies (8) 8
colorectal neoplasms - drug therapy (7) 7
docetaxel (7) 7
medicine & public health (7) 7
neoplasm staging (7) 7
toxicity (7) 7
trial (7) 7
women (7) 7
double-blind (6) 6
drug administration schedule (6) 6
open-label (6) 6
product development (6) 6
1st-line treatment (5) 5
abridged index medicus (5) 5
adjuvant treatment (5) 5
antimitotic agents (5) 5
antineoplastic agents (5) 5
bone neoplasms - secondary (5) 5
carcinoma (5) 5
colorectal neoplasms - pathology (5) 5
deoxycytidine - administration & dosage (5) 5
deoxycytidine - analogs & derivatives (5) 5
doxorubicin (5) 5
epirubicin - administration & dosage (5) 5
erbb-2 protein (5) 5
fluorouracil - administration & dosage (5) 5
fluorouracil - analogs & derivatives (5) 5
hodgkin disease - pathology (5) 5
hodgkin's disease (5) 5
irinotecan (5) 5
lung neoplasms - drug therapy (5) 5
medical prognosis (5) 5
metastases (5) 5
motivation (5) 5
multicenter (5) 5
netherlands - epidemiology (5) 5
neutropenia (5) 5
organoplatinum compounds - administration & dosage (5) 5
oxaliplatin (5) 5
retrospective studies (5) 5
safety (5) 5
age (4) 4
antibodies, monoclonal - administration & dosage (4) 4
antibodies, monoclonal, humanized (4) 4
cancer patients (4) 4
clinical-trials (4) 4
combination chemotherapy (4) 4
cyclophosphamide (4) 4
design (4) 4
disease (4) 4
dna, neoplasm - analysis (4) 4
drug dosages (4) 4
endocrine therapy (4) 4
fatigue (4) 4
fluorouracil (4) 4
granulocyte colony-stimulating factor - therapeutic use (4) 4
hodgkin disease - genetics (4) 4
kaplan-meier estimate (4) 4
liver neoplasms - secondary (4) 4
metastatic breast cancer (4) 4
netherlands (4) 4
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range

by Coebergh van den Braak, R. R. J and van Rijssen, L. B and van Kleef, J. J and Vink, G. R and Berbee, M and van Berge Henegouwen, M. I and Bloemendal, H. J and Bruno, M. J and Burgmans, M. C and Busch, O. R. C and Coene, P. P. L. O and Coupé, V. M. H and Dekker, J. W. T and van Eijck, C. H. J and Elferink, M. A. G and Erdkamp, F. L. G and van Grevenstein, W. M. U and de Groot, J. W. B and van Grieken, N. C. T and de Hingh, I. H. J. T and Hulshof, M. C. C. M and Ijzermans, J. N. M and Kwakkenbos, L and Lemmens, V. E. P. P and Los, M and Meijer, G. A and Molenaar, I. Q and Nieuwenhuijzen, G. A. P and de Noo, M. E and van de Poll-Franse, L. V and Punt, C. J. A and Rietbroek, R. C and Roeloffzen, W. W. H and Rozema, T and Ruurda, J. P and van Sandick, J. W and Schiphorst, A. H. W and Schipper, H and Siersema, P. D and Slingerland, M and Sommeijer, D. W and Spaander, M. C. W and Sprangers, M. A. G and Stockmann, H. B. A. C and Strijker, M and van Tienhoven, G and Timmermans, L. M and Tjin-a-Ton, M. L. R and van der Velden, A. M. T and Verhaar, M. J and Verkooijen, H. M and Vles, W. J and de Vos-Geelen, J. M. P. G. M and Wilmink, J. W and Zimmerman, D. D. E and van Oijen, M. G. H and Koopman, M and Besselink, M. G. H and van Laarhoven, H. W. M and PLCRC Working Grp and Dutch Upper GI Canc Grp and Dutch Pancreatic Canc Grp and Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group and for the Dutch Pancreatic Cancer Group, Dutch Upper GI Cancer Group and PLCRC working group
Acta Oncologica, ISSN 0284-186X, 02/2018, Volume 57, Issue 2, pp. 195 - 202
Background: The increasing sub-classification of cancer patients due to more detailed molecular classification of tumors, and limitations of current trial... 
Journal Article
Lancet, The, ISSN 0140-6736, 2015, Volume 385, Issue 9980, pp. 1843 - 1852
Journal Article
Annals of oncology, ISSN 0923-7534, 2008, Volume 19, Issue 4, pp. 734 - 738
Journal Article
Lancet, The, ISSN 0140-6736, 2007, Volume 370, Issue 9582, pp. 135 - 142
Journal Article
Breast Cancer Research and Treatment, ISSN 0167-6806, 07/2011, Volume 128, Issue 2, pp. 437 - 445
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2009, Volume 360, Issue 6, pp. 563 - 572
Capecitabine, oxaliplatin, and bevacizumab are standard treatment for metastatic colorectal cancer. This trial tested whether adding cetuximab to this... 
CAPECITABINE | GROWTH-FACTOR RECEPTOR | MEDICINE, GENERAL & INTERNAL | LEUCOVORIN | PLUS OXALIPLATIN | FINAL REPORT | PHASE-III | COMBINATION CHEMOTHERAPY | IRINOTECAN | 1ST-LINE THERAPY | FLUOROURACIL | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Capecitabine | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Bevacizumab | Antibodies, Monoclonal, Humanized | Organoplatinum Compounds - administration & dosage | Receptor, Epidermal Growth Factor - metabolism | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Colorectal Neoplasms - drug therapy | Treatment Failure | Aged, 80 and over | Adult | Female | Cetuximab | Receptor, Epidermal Growth Factor - immunology | Fluorouracil - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quality of Life | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Mutation | Colorectal Neoplasms - pathology | Deoxycytidine - analogs & derivatives | Care and treatment | Chemotherapy | Usage | Health aspects | Colorectal cancer | Cancer | Clinical trials | Cancer therapies | Medical treatment | Committees | Index Medicus | Abridged Index Medicus
Journal Article
Annals of oncology, ISSN 0923-7534, 2017, Volume 28, Issue 9, pp. 2128 - 2134
Journal Article
by Fuchs, Charles S and Shitara, Kohei and Di Bartolomeo, Maria and Lonardi, Sara and Al-Batran, Salah-Eddin and Van Cutsem, Eric and Ilson, David H and Alsina, Maria and Chau, Ian and Lacy, Jill and Ducreux, Michel and Mendez, Guillermo Ariel and Alavez, Alejandro Molina and Takahari, Daisuke and Mansoor, Wasat and Enzinger, Peter C and Gorbounova, Vera and Wainberg, Zev A and Hegewisch-Becker, Susanna and Ferry, David and Lin, Ji and Carlesi, Roberto and Das, Mayukh and Shah, Manish A and Luft, Alexander V and Karaseva, Nina A and Kowalyszyn, Rubén Dario and Hernandez, Carlos Alberto and Csoszi, Tibor and De Vita, Ferdinando and Pfeiffer, Per and Sugimoto, Naotoshi and Kocsis, Judit and Csilla, Andràs and Bodoky, Gyorgy and Garnica Jaliffe, Georgina and Protsenko, Svetlana and Madi, Ayman and Wojcik, Elzbieta and Brenner, Baruch and Folprecht, Gunnar and Sarosiek, Tomasz and Peltola, Katriina Johanna and Bono, Peter and Ayala, Hubert and Aprile, Giuseppe and Gerardo, Cardellino Giovanni and Huitzil Melendez, Fidel David and Falcone, Alfredo and Di Costanzo, Francesco and Tehfe, Moustapha and Mineur, Laurent and García Alfonso, Pilar and Obermannova, Radka and Senellart, Hélène and Petty, Russell and Samuel, Leslie and Acs, Peter Istvan and Hussein, Maen Abdelkarim and Nechaeva, Marina N and Erdkamp, F.L.G and Won, Elizabeth and Bendell, Johanna Chock and Gallego Plazas, Javier and Lorenzen, Sylvie and Melichar, Bohuslav and Escudero, Miguel Angel and Pezet, Denis and Phelip, Jean-Marc and Kaen, Diego Lucas and Reeves, James A. Jr and Longo Muñoz, Federico and Madhusudan, Srinivasan and Barone, Carlo and Fein, Luis Enrique and Gomez Villanueva, Angel and Hebbar, Mohamed and Prausova, Jana and Visa Turmo, Laura and Vidal Barrull, Joana and Yilmaz, Mette Karen Nytoft and Beny, Alex and Van Laarhoven, H.M.W and DiCarlo, Brian Anthony and Esaki, Taito and Fujitani, Kazumasa and Geboes, Karen and Geva, Ravit and Kadowaki, Shigenori and Leong, Stephen and Machida, Nozomu and Raj, Moses Sundar and Ramirez Godinez, Francisco Javier and Ruzsa, Agnes and Ford, Hugo and Lawler, William E and Maisey, Nicolas Robert and Petera, Jiri and Shacham-Shmueli, Einat and Sinapi, Isabelle and ... and RAINFALL Study Group and RAINFALL Study Grp
The Lancet Oncology, ISSN 1470-2045, 03/2019, Volume 20, Issue 3, pp. 420 - 435
VEGF and VEGF receptor 2 (VEGFR-2)-mediated signalling and angiogenesis can contribute to the pathogenesis and progression of gastric cancer. We aimed to... 
EXPOSURE-RESPONSE | MULTICENTER | GASTROESOPHAGEAL JUNCTION | ANGIOGENESIS | ONCOLOGY | BEVACIZUMAB | COMBINATION | CANCER | EXPRESSION | CHEMOTHERAPY | ENDOTHELIAL GROWTH-FACTOR | Adenocarcinoma | Antimitotic agents | Care and treatment | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Rain and rainfall
Journal Article
by Tjan-Heijnen, Vivianne C G and van Hellemond, Irene E G and Peer, Petronella G M and Swinkels, Astrid C P and Smorenburg, Carolien H and van der Sangen, Maurice J C and Kroep, Judith R and De Graaf, Hiltje and Honkoop, Aafke H and Erdkamp, Frans L G and van den Berkmortel, Franchette W P J and de Boer, Maaike and de Roos, Wilfred K and Linn, Sabine C and Imholz, Alexander L T and Seynaeve, Caroline M and Kitzen, J.J.E.M and Strobbe, L.J.A and Kouwenhoven, E.A and van Dalen, T and van Overbeeke, A.J and Nuytinck, J.K.S and Arntz, I.E and Blaisse, R.J.B and Stockmann, H.B.A.C and Nijhuis, P.H.A and Veldhuis, G.J and Mastboom, W.J.B and van Riel, J.M.G.H and van Dam, J.H and den Boer, M.O and Agterof, M.J and de Roos, M.A.J and Roumen, R.M.H and van der Hoeven, J.J.M and Beeker, A and Koelemij, R and van Bochove, A and Madretsma, G.S and Siemerink, E.J.M and Guicherit, O.R and Vos, A.H and Nieuwenhuijzen, G.A.P and Kehrer, D.F.S and Valster, F.A.A and Tanis, B.C and van Voorthuizen, T and van der Velden, A.M.T and Hellingman, R.A and Vree, R and van Rossum-Schornagel, Q and Meerum Terwogt, J.M and van Leeuwen-Breuk, W.G and Haasjes, J.G and Davidis-van Schoonhoven, M.A and Vriens, E.J.C and Jagers, M and Muller, E.W and Schiphorst, P.P.J.B.M and van Groeningen, C.J and van Dijk, M.A and Janssens- van Vliet, E and Schepers, E.E.M and Merkus, J.W.S and van Diemen, N.G.J and van Doorn, R.C and Bosscha, K and den Toom, R and van der Velden, P.C and van Rossum, C.T.A.M and Oosterkamp, H.M and van Hillegersberg, R and Jas, B and Weernink, E.E.M and Ketel, J.M.A and Jansen, J.J and Maring, J.K and Govaert, M.J.P.M and Kamm, Y.J.L and Vleugel, M.M and Hovenga, S and de Boer, J and Potthoff, H and Sommeijer, D.W and van Dulken, E.J and Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators and Dutch Breast Canc Res Grp B
The Lancet Oncology, ISSN 1470-2045, 11/2017, Volume 18, Issue 11, pp. 1502 - 1511
The effect of extended adjuvant aromatase inhibition in hormone receptor-positive breast cancer after sequential endocrine therapy of tamoxifen followed by an... 
Journal Article
by Petrylak, Daniel P and de Wit, Ronald and Chi, Kim N and Drakaki, Alexandra and Sternberg, Cora N and Nishiyama, Hiroyuki and Castellano, Daniel and Hussain, Syed and Fléchon, Aude and Bamias, Aristotelis and Yu, Evan Y and van der Heijden, Michiel S and Matsubara, Nobuaki and Alekseev, Boris and Necchi, Andrea and Géczi, Lajos and Ou, Yen-Chuan and Coskun, Hasan Senol and Su, Wen-Pin and Hegemann, Miriam and Percent, Ivor J and Lee, Jae-Lyun and Tucci, Marcello and Semenov, Andrey and Laestadius, Fredrik and Peer, Avivit and Tortora, Giampaolo and Safina, Sufia and del Muro, Xavier Garcia and Rodriguez-Vida, Alejo and Cicin, Irfan and Harputluoglu, Hakan and Widau, Ryan C and Liepa, Astra M and Walgren, Richard A and Hamid, Oday and Zimmermann, Annamaria H and Bell-McGuinn, Katherine M and Powles, Thomas and Wong, Suet-Lai Shirley and Tan, Thean Hsiang and Hovey, Elizabeth Jane and Clay, Timothy Dudley and Ng, Siobhan Su Wan and Rutten, Annemie and Machiels, Jean-Pascal and Dumez, Herlinde and Cheng, Susanna Yee-Shan and Chi, Kim Nguyen and Ferrario, Cristiano and Sengeloev, Lisa and Jensen, Niels Viggo and Thibault, Constance and Laguerre, Brigitte and Laestadius, Fredrik and Joly, Florence and Flechon, Aude and Culine, Stéphane and Becht, Catherine and Niegisch, Günter and Stöckle, Michael and Grimm, Marc-Oliver and Gakis, Georgios and Schultze-Seemann, Wolfgang and Kalofonos, Haralambos and Mavroudis, Dimitrios and Papandreou, Christos and Karavasilis, Vasilis and Bamias, Aristotelis and Révész, Janos and Geczi, Lajos and Rosenbaum, Eli and Leibowitz-Amit, Raya and Kejzman, Daniel and Peer, Avivit and Sarid, David and Scagliotti, Giorgio Vittorio and Sternberg, Cora N and Tortora, Giampaolo and Bracarda, Sergio and Necchi, Andrea and Massari, Francesco and Osawa, Takahiro and Miyajima, Naoto and Shinohara, Nobuo and Fukuta, Fumimasa and Ohyama, Chikara and Obara, Wataru and Yamashita, Shinichi and Tomita, Yoshihiko and Kawai, Koji and Fukasawa, Satoshi and Matsubara, Nobuaki and Oyama, Masafumi and Yonese, Junji and Nagata, Masayoshi and Uemura, Motohide and Nishimura, Kazuo and Kawakita, Mutsushi and Tsunemori, Hiroyuki and ... and RANGE study investigators and RANGE Study Investigators
The Lancet, ISSN 0140-6736, 11/2017, Volume 390, Issue 10109, pp. 2266 - 2277
Few treatments with a distinct mechanism of action are available for patients with platinum-refractory advanced or metastatic urothelial carcinoma. We assessed... 
BREAST-CANCER | BLADDER-CANCER | LUNG-CANCER | 2ND-LINE THERAPY | TRANSITIONAL-CELL-CARCINOMA | FOLLOW-UP | OPEN-LABEL | FACTOR RECEPTOR-2 | II TRIAL | ENDOTHELIAL GROWTH-FACTOR | MEDICINE, GENERAL & INTERNAL | CISPLATIN | DOXORUBICIN | METHOTREXATE | VINBLASTINE | COMBINATION | Carcinoma, Transitional Cell - mortality | Prognosis | Humans | Middle Aged | Male | Neoplasm Invasiveness - pathology | Urinary Bladder Neoplasms - pathology | Adult | Female | Urinary Bladder Neoplasms - mortality | Double-Blind Method | Risk Assessment | Docetaxel | Kaplan-Meier Estimate | Proportional Hazards Models | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Disease-Free Survival | Taxoids - administration & dosage | Carcinoma, Transitional Cell - pathology | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Internationality | Neoadjuvant Therapy - methods | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Neoplasm Staging | Antimitotic agents | Care and treatment | Carcinoma | Analysis | Clinical trials | Product development | Metastasis | Antineoplastic agents | Cancer | Cytotoxicity | Oncology | Patients | Cancer therapies | Evidence-based medicine | Metastases | Angiogenesis | Chemotherapy | Platinum | Medical prognosis | Ligands | Clinical medicine | Urothelial carcinoma | Vascular endothelial growth factor | Apoptosis
Journal Article